OSCR
Oscar Health, Inc.
OSCR has the edge over RDY overall, supported by stronger fundamentals and stronger modeled upside.
RDY
Dr. Reddy's Laboratories Limited
RDY has lower modeled downside risk, despite its lower overall score.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
RDY Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Under pressure | |
| Healthy |
RDY's balance sheet is currently healthy, and its revenue and profitability are stable, but its cash flow is under pressure.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over RDY in the historical PE scenario, which offers more potential upside but is not a forecast.
RDY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 19x | $6.94 | -53% |
| Fair | 31x | $11.07 | -25% |
| Current | 41x | $14.73 | — |
| Expensive | 43x | $15.47 | +5% |
Historical ranges are pointers, not guarantees.
RDY's PE is 41x, but its earnings don't support one, so it isn't a reliable read right now.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
RDY Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for RDY, with profitability improving.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
RDY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.36 | -52% |
| Q2 2026 | $0.42 | -42% |
| Q1 2026 | $0.55 | -24% |
| Q4 2025 | $0.72 | +4.3% |
| Q3 2025 | $0.75 | +10% |
RDY's earnings per share have fallen from their peak: $0.36 over the past year, against $0.75 in late 2025.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over RDY on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
RDY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $923.8M | -1.7% |
| Q2 2026 | $866.1M | -5% |
| Q1 2026 | $814.3M | -10% |
| Q4 2025 | $931M | +4.4% |
| Q3 2025 | $939.3M | +9.8% |
| Q2 2025 | $911.6M | +11% |
| Q1 2025 | $907.4M | +20% |
| Q4 2024 | $891.7M | +16% |
RDY's revenue grew through 2024 and has held roughly level since: $924M last quarter, down 1.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 14% | -6.2 points |
| Q2 2026 | 3.7% | -17 points |
| Q1 2026 | 0.6% | -20 points |
| Q4 2025 | 16% | -6.1 points |
| Q3 2025 | 20% | -2 points |
| Q2 2025 | 20% | -2.9 points |
| Q1 2025 | 21% | -0.4 points |
| Q4 2024 | 22% | -1.5 points |
RDY has the edge over OSCR on profitability, with a higher operating margin.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over RDY on cash flow, with more consistent year-over-year improvement.
RDY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $24.6M | -58% |
| Q2 2026 | -$49.4M | -203% |
| Q1 2026 | $114.7M | 0% |
| Q4 2025 | $38.3M | +$61.7M |
| Q3 2025 | $58M | +286% |
| Q2 2025 | $47.8M | +116% |
| Q1 2025 | $114.7M | +14646% |
| Q4 2024 | -$23.5M | -30999% |
RDY still generates free cash flow, though less than at its 2022 peak: $128M over the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
RDY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +662K shares |
| 1 year | 0% | +313K shares |
| 3 years | +0.2% | +1.4M shares |
RDY has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $14.8M |
| Q4 2024 | — |
RDY hasn't bought back shares in the past year.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over RDY on leverage, with a lower net debt burden relative to earnings.
RDY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.1x | Healthy |
| Q2 2026 | 1.0x | Very low |
| Q1 2026 | 0.8x | Very low |
| Q4 2025 | 0.5x | Very low |
| Q3 2025 | 0.5x | Very low |
| Q2 2025 | 0.4x | Very low |
| Q1 2025 | 0.3x | Very low |
| Q4 2024 | 0.4x | Very low |
RDY's net debt is about 1.1 years of its operating earnings (EBITDA), up from less than a year a year ago.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
RDY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 66.4 | Neutral |
| Stochastic | 94.8 | Overbought |
RDY's weekly RSI is 66 (neutral) and its Stochastic is 95 (overbought).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over RDY on valuation relative to its sector.
RDY PE vs Healthcare Sector
| Metric | RDY | Sector median | Relative |
|---|---|---|---|
| PE | 41x | 26x | 57% above |
| PE % | 74 | 29 | 45 pts above |
RDY is trading at 41x earnings, a 57% premium to the Healthcare sector's median of 26x, though its earnings don't support one.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
RDY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $13.4 | 10% above |
| 20 week MA | $12.8 | 15% above |
| 50 week MA | $13.4 | 10% above |
| 100 week MA | $13.8 | 6.8% above |
| 200 week MA | $13.8 | 7% above |
RDY is in an uptrend: it's above all five of its weekly moving averages, and 7% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over RDY on returns for 2026, with the stronger performance.
RDY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $8.12 | $14.1 | +74% |
| 2021 | $14.1 | $12.6 | -11% |
| 2022 | $12.6 | $10.5 | -16% |
| 2023 | $10.5 | $13.9 | +32% |
| 2024 | $13.9 | $15.9 | +14% |
| 2025 | $15.9 | $14.2 | -11% |
| 2026 YTD | $14.2 | $14.7 | +4% |
RDY has finished lower in three of the last six years. It's up 4% so far in 2026.